WEBULL
News
VERV
11.13
0.00%
0.00
Eli Lilly Reports Q2 2025 Revenue Surge of 38% to $15.56 Billion, EPS Up 92% to $6.29
Reuters · 08/07/2025 10:46
Weekly Report: what happened at VERV last week (0721-0725)?
Weekly Report · 07/28/2025 09:28
*News On Verve Therapeutics Inc. (VERV) Now Under LLY
Dow Jones · 07/25/2025 21:08
Verve Therapeutics Announces Merger and Nasdaq Delisting
TipRanks · 07/25/2025 20:51
Verve Therapeutics Inc. Announces Delisting from Nasdaq Following Merger Completion
Reuters · 07/25/2025 20:17
Eli Lilly completes acquisition of Verve Therapeutics
TipRanks · 07/25/2025 12:56
*Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV
Dow Jones · 07/25/2025 12:49
Eli Lilly And Verve Therapeutics Announces That The Tender Offer For All Outstanding Verve Shares, Priced At $10.50 Per Share In Cash Plus A Potential Additional $3.00 Via A Non-Tradable Contingent Value Right, Officially Expired At 12:01 A.M. Et On July 24, 2025. The Offer Was Not Extended.
Benzinga · 07/24/2025 12:05
*Eli Lilly Expects to Complete Verve Acquisition on July 25 >LLY VERV
Dow Jones · 07/24/2025 12:02
*Eli Lilly: About 55.7% of Verve Shares Tendered >LLY VERV
Dow Jones · 07/24/2025 12:01
ELI LILLY AND CO - TENDER OFFER FOR VERVE SHARES AT $10.50 PER SHARE
Reuters · 07/24/2025 12:00
*Lilly and Verve Announce Expiration of Verve Tender Offer
Dow Jones · 07/24/2025 12:00
Press Release: Lilly and Verve announce expiration of Verve tender offer
Dow Jones · 07/24/2025 12:00
After Hours Most Active for Jul 23, 2025 : TSLL, INTC, KVUE, VERV, GOOGL, GOOG, NVDA, PATH, CMG, RKT, KMI, QS
NASDAQ · 07/23/2025 20:24
Noteworthy Wednesday Option Activity: WEN, HAS, VERV
NASDAQ · 07/23/2025 19:26
Weekly Report: what happened at VERV last week (0714-0718)?
Weekly Report · 07/21/2025 09:27
Verve Therapeutics Announces Retention Bonus Program for Executives
TipRanks · 07/15/2025 10:45
Verve Therapeutics Inc. Announces Retention Bonus Plan for Key Executives Amid Pending Acquisition
Reuters · 07/15/2025 10:17
Weekly Report: what happened at VERV last week (0707-0711)?
Weekly Report · 07/14/2025 09:28
Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs. -- Heard on the Street
The Wall Street Journal · 07/13/2025 10:30
More
Webull provides a variety of real-time VERV stock news. You can receive the latest news about Verve Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VERV
Verve Therapeutics, Inc. is a clinical-stage company. The Company is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.